All In Biotech

Drug Trial Radar · NCT03962738

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 846 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

846

Actual

Start

May 31, 2019

Primary completion

Jun 8, 2020

Study completion Jun 8, 2020

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.

Conditions

  • Migraine

Interventions

  • LasmiditanDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Are Headache Pain Free In High Dose Group (200 mg Lasmiditan)Time frame: 2 Hours Postdose

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Doi Clinic Internal Medicine Neurology

    Hiroshima, Japan

  • Tanaka neurosurgical clinic

    Kagoshima, Japan

  • Umenotsuji Clinic

    Kochi, Japan

  • Kumamoto City Hospital

    Kumamoto, Japan

  • Tatsuoka Neurology Clinic

    Kyoto, Japan

  • Ishikawa Clinic

    Kyoto, Japan

  • Osaka Saiseikai Nakatsu Hospital

    Osaka, Japan

  • Tominaga Hospital

    Osaka, Japan

  • Japanese Red Cross Shizuoka Hospital

    Shizuoka, Japan

  • Takanoko Hospital

    Matsuyama, Ehime, Japan

  • Ikeda Neurosurgical Clinic

    Kasuga-shi, Fukuoka, Japan

  • Jinnouchi Neurosurgery Clinic

    Kasuga-shi, Fukuoka, Japan

  • SUBARU Health Insurance Society Ota Memorial Hospital

    Ota-shi, Gunma, Japan

  • Nakamura Memorial Hospital

    Sapporo, Hokkaido, Japan

  • Kohnan Hospital

    Kobe, Hyōgo, Japan

  • Nishinomiya Municipal Central Hospital

    Nishinomiya, Hyōgo, Japan

  • Yamaguchi Clinic

    Nishinomiya-shi, Hyōgo, Japan

  • Fujitsu Clinic

    Kawasaki, Kanagawa, Japan

  • Sendai Headache and Neurology Clinic

    Sendai, Miyagi, Japan

  • Okayama City General Medical Center Okayama City Hospital

    Okayama, Okayama-ken, Japan

  • Chibune General Hospital

    Osaka, Osaka, Japan

  • Takase internal medicine clinic

    Toyonaka-shi, Osaka, Japan

  • Osoegawa Neurology Clinic

    Saga, Saga-ken, Japan

  • Saitama Medical University Hospital

    Iruma-Gun, Saitama, Japan

  • Saitama Neuropsychiatric Institute

    Saitama, Saitama, Japan

  • Saino Clinic

    Tokorozawa, Saitama, Japan

  • Dokkyo Medical University Hospital

    Shimotsuga-Gun, Tochigi, Japan

  • Niwa Family Clinic

    Chofu-shi, Tokyo, Japan

  • Sanno Clinic Shinagawa

    Minato-ku, Tokyo, Japan

  • USUDA CLINIC for internal medicine

    Setagaya-ku, Tokyo, Japan

  • Tokyo Headache Clinic

    Shibuya-ku, Tokyo, Japan

  • Fukuuchi Pain Clinic

    Shinjuku-ku, Tokyo, Japan

  • Sakura Clinic Internal Medicine Neurology

    Toyama, Toyama, Japan

  • Nagaseki Headache Clinic

    Kai-Shi, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.